NCT06767527View on ClinicalTrials.gov

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
DRUG

AK112

AK112 via intravenous (IV) infusion

DRUG

Nab-paclitaxel

Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle

DRUG

Placebo

Placebo via IV infusion

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT06767527 - AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | Biotech Hunter | Biotech Hunter